More large trials needed to decide best duration of treatment with tamoxifen
- 28 November 1998
- Vol. 317 (7171), 1524
- https://doi.org/10.1136/bmj.317.7171.1524
Abstract
EDITOR—I agree with Rea et al that we do not know the optimum duration of adjuvant tamoxifen treatment.1 The data that they presented, however, suggest that the trials they advocated—ATLAS (adjuvant tamoxifen longer against shorter) and aTTom (adjuvant tamoxifen treatment offers more?)—may still fail to resolve this issue. The most recent overview, which provides much indirect evidence, suggests that five years is better than two, but it also reports a non-significant trend for the incidence of endometrial cancer to …Keywords
This publication has 5 references indexed in Scilit:
- Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.1998
- Adjuvant tamoxifen: how long before we know how long?BMJ, 1998
- Postchemotherapy Adjuvant Tamoxifen Therapy Beyond Five Years in Patients With Lymph Node-Positive Breast CancerJNCI Journal of the National Cancer Institute, 1996
- Five Versus More Than Five Years of Tamoxifen Therapy for Breast Cancer Patients With Negative Lymph Nodes and Estrogen Receptor-Positive TumorsJNCI Journal of the National Cancer Institute, 1996
- Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancerBritish Journal of Cancer, 1996